Our
Team

Our world-class, multidisciplinary team of psychedelic, drug development, commercialisation and digital experts are united by their determination to help people living with neuropsychiatric disorders.

Our
Executive
Team
Dr. Frank Wiegand
Chief Medical Officer
Dr. Frank Wiegand
Chief Medical Officer
Frank is a German-trained neurologist and neuroscientist who joins us after a 21-year career with Johnson & Johnson, where he most recently was the VP of Global Medical Affairs, Neurosciences. Over his 2 decades in the biotechnology industry, Frank has worked on more than 30 different new molecular entities across multiple neurological and psychiatric indications and most recently contributed significantly to the development and approval of Esketamine as a treatment for Treatment-Resistant-Depression (TRD) and suicidality, the first true advancement in the psychedelics field. Frank has held positions of increasing responsibility in Marketing & Sales with Janssen-Cilag in Germany, in Global Strategic Marketing, Medical Affairs, Market Access as well as R&D functions, and his broad experience will serve Beckley Psytech well. Dr. Wiegand received his M.D. and PhD. from the Heinrich Heine University of Düsseldorf and completed his fellowship training as a Neurologist at the University of Essen in Germany. He also obtained extensive additional training in neuropharmacology, specifically cerebral ischemia, from the Humboldt University Berlin, where he worked as post-doctoral fellow with funding from the German Stoke Research Foundation. In 2002 he received a Postgraduate Certificate in Business Administration from the Herriot Watt University, Edinburgh, Scotland. Frank is a member of several scientific societies and associations, published multiple peer-reviewed journal articles and book chapters about translational medicine and achieved numerous business and leadership awards.
Our
Board
of
Directors
Our
Scientific
Advisors
Our
Investors

Dr. Robin L Carhart-Harris

Professor Matthew W Johnson PhD

Other investors include investment entities (e.g. funds and family offices) and individuals.